New virologic reagents for neutralizing antibody assays

Current Opinion in HIV and AIDS

Volumn 4, Issue 5, 2009, Pages 418-425

  Ochsenbauer, Christina ^a   Kappes, John C ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Neutralizing antibody; Pseudovirion assay; Renilla luciferase; Replication competent reporter virus; Vaccine assessment

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; CELL ASSAY; CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; VIROLOGY; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; CLINICAL LABORATORY TECHNIQUES; HIV ANTIBODIES; HIV-1; HUMANS; INDICATORS AND REAGENTS; NEUTRALIZATION TESTS;

EID: 69549105767     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32832f011e     Document Type: Review

References (69)

1. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006; 24:227-255.
2. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24:739-769.
3. Haynes BF, Montefiori DC. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 2006; 5:579-595. (Pubitemid 44627888)
4. Phogat S, Wyatt RT, Karlsson Hedestam GB. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med 2007; 262:26-43. (Pubitemid 47000631)
5. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262:5-25. Although not published in the review period, this paper is an excellent and comprehensive review of the past 20 years of research on the NAb response to HIV-1. This research is placed into context with various mechanisms by which antibodies may inhibit HIV-1 and many challenges for exploiting humoral immunity for prevention or therapy for both.
6. Karlsson-Hedestam GB, Fouchier RA, Phogat S, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008; 6:143-155.
7. Nara PL, Lin G. HIV-1: the confounding variables of virus neutralization. Curr Drug Targets Infect Disord 2005; 5:157-170. (Pubitemid 40974795)
8. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
9. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236. (Pubitemid 38332116)
10. Johnson WE, Desrosiers RC. Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med 2002; 53:499-518.
11. Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420:678-682.
12. Fenyo EM, Heath A, Dispinseri S, et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE 2009; 4:e4505. This article describes results of an international collaboration using several different assay formats to evaluate neutralizing reagents against a panel of reference viruses. Differences in neutralization assay sensitivity were observed depending on both the assay and neutralizing reagent, and a range of neutralizing assays is recommended for evaluating NAb responses elicited by vaccines.
13. Montefiori D, Sattentau Q, Flores J, et al. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 2007; 4:e348. Although not published in the review period, this report remains highly relevant as it summarizes discussions from a Global HIV Vaccine Enterprise Working Group convened in May of 2007. It conveys an important perspective of key scientific issues and opportunities related to the challenges of eliciting protective humoral immune responses, including that of immunogen design and assay validation and standardization.
14. Polonis VR, Brown BK, Rosa Borges A, et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008; 375:315-320. This minireview provides an excellent overview of various assays used to analyze NAb activity against HIV-1. As newer assays have been developed, it compares technologic differences and relates this to discordant results observed between pseudovirion/reporter cell line and PBMC assays and NAbs. The article also provides perspective on the challenges and significance of developing and validating standardize assay platforms that will be of predictive value for protecting humans against HIV-1 transmission.
15. Mascola JR, Sambor A, Beaudry K, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 2005; 79:771-779. (Pubitemid 40053860)
16. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996; 173:340-348.
17. Matthews TJ. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses 1994; 10:631-632.
18. Moore JP, Cao Y, Qing L, et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995; 69:101-109. (Pubitemid 24378783)
19. Wrin T, Loh TP, Vennari JC, et al. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995; 69:39-48. (Pubitemid 24378776)
20. Prado I, Fouts TR, Dimitrov AS. Neutralization of HIV by antibodies. Methods Mol Biol 2009; 525:517-531; xiv. This review article suggests that the PBMC-based neutralization assay represents a closer approximation of conditions for HIV-1 neutralization in vivo and provides important experimental details, including experimental protocols, for using PBMCs to analyzing NAb activity.
21. Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, et al. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J Virol 2007; 81:8533-8542. (Pubitemid 47242826)
22. Spenlehauer C, Kirn A, Aubertin AM, et al. Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition. J Virol 2001; 75:2235-2245. (Pubitemid 32147562)
23. D'Souza MP, Livnat D, Bradac JA, et al. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J Infect Dis 1997; 175:1056-1062. (Pubitemid 27176491)
24. Gauduin MC, Allaway GP, Maddon PJ, et al. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules. J Virol 1996; 70:2586-2592. (Pubitemid 26089853)
25. Mascola JR, Louder MK, Winter C, et al. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J Virol 2002; 76:4810-4821. (Pubitemid 34441687)
26. Darden JM, Polonis VR, deSouza MS, et al. A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates. Cytometry 2000; 40:141-150.
27. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 2009; 485:395-405. An excellent review of a widely used reporter cell line (TZMbl) and pseudovirus technology and standardization efforts that have become integral to the HIV Vaccine Trials Network.
28. Mascola JR, D'Souza P, Gilbert P, et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005; 79:10103-10107. This important and still highly relevant commentary addresses the requirements for immunologic assessment of current and new HIV-1 vaccine immunogens and, based on recent technological advances, makes recommendation for assays that exploit standardized reference panels of pseudoviruses.
29. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-928. (Pubitemid 30165271)
30. Richman DD, Wrin T, Little SJ, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149. (Pubitemid 36418171)
31. Binley JM, Lybarger EA, Crooks ET, et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008; 82:11651-11668.
32. Herrera C, Klasse PJ, Michael E, et al. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 2005; 338:154-172. (Pubitemid 40835934)
33. Willey RL, Shibata R, Freed EO, et al. Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures. J Virol 1996; 70:6431-6436. (Pubitemid 26266868)
34. Bastiani L, Laal S, Kim M, et al. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol 1997; 71:3444-3450. (Pubitemid 27172354)
35. Fortin JF, Cantin R, Lamontagne G, et al. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997; 71:3588-3596. (Pubitemid 27172369)
36. Hioe CE, Chien PC Jr, Lu C, et al. LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission. J Virol 2001; 75:1077-1082. (Pubitemid 32037313)
37. Rizzuto CD, Sodroski JG. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 1997; 71:4847-4851. (Pubitemid 27204183)
38. Sawyer LS, Wrin MT, Crawford-Miksza L, et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994; 68:1342-1349. (Pubitemid 24065696)
39. Zhang YJ, Fredriksson R, McKeating JA, et al. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology 1997; 238:254-264. (Pubitemid 28218143)
40. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
41. Platt EJ, Wehrly K, Kuhmann SE, et al. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage tropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:2855-2864. (Pubitemid 28175522)
42. Ochsenbauer-Jambor C, Jones J, Heil M, et al. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. Biotechniques 2006; 40:91-100. (Pubitemid 46534944)
43. Jones J, Whitford W, Wagner F, et al. Optimization of HIV-1 infectivity assays. Biotechniques 2007; 43:589-590; 592, 594.
44. Brown BK, Karasavvas N, Beck Z, et al. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J Virol 2007; 81:2087-2091. (Pubitemid 46214483)
45. Moody M, Plonk M, Fuller L, et al. Antilipid human monoclonal antibodies inhibit HIV-1 infection of PBMC by binding to host cells. AIDS Research and Human Retroviruses 2008; 24:13; Oral Abstract OA03-06 from AIDS Vaccine 2008.
46. Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252. (Pubitemid 39507829)
47. Brown BK, Wieczorek L, Sanders-Buell E, et al. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008; 375:529-538. This study provides a systematic comparison of PBMC-based and pseudovirion-based neutralization assays and results obtained from them.
48. Choudhry V, Zhang MY, Harris I, et al. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun 2006; 348:1107-1115. (Pubitemid 44251203)
49. Ketas TJ, Kuhmann SE, Palmer A, et al. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 2007; 364:281-290. (Pubitemid 46873702)
50. Lee B, Sharron M, Montaner LJ, et al. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A 1999; 96:5215-5220. (Pubitemid 29214563)
51. Edmonds T, Ding D, Conway J, et al. Rapid and quantitative analysis of HIV-1 neutralization in primary cells via Renilla Luciferase-expressing infectious molecular clones [abstract number 328a]. Conference on Retroviruses and Opportunistic Infections; 2009. This work described the concept and development for generation and application of the pNL-LucR.T2A backbone. Results are shown that validate utility of the novel reporter, stability of the Renilla luciferase, and analysis of NAb activity in various target cells, including PBMCs.
52. Donnelly ML, Luke G, Mehrotra A, et al. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol 2001; 82 (Pt 5):1013-1025.
53. Freed EO, Martin MA. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J Virol 1995; 69:1984-1989.
54. Daly TJ, Cook KS, Gray GS, et al. Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature 1989; 342:816-819.
55. Rosen CA, Terwilliger E, Dayton A, et al. Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci U S A 1988; 85:2071-2075. (Pubitemid 24315830)
56. Simon-Loriere E, Galetto R, Hamoudi M, et al. Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus. PLoS Pathog 2009; 5:e1000418. This article describes a study of genetic recombination that occurs naturally in the HIV/AIDS pandemic between the env genes of primary HIV-1 viruses belonging to different viral clades. By determining the locations of recombination breakpoints across the HIV-1 envelope gene and purifying selection acting against dysfunctional recombinants, this article further argues for the validity of the molecular strategy employed to insert/analyze the env-ecto domain of other viral strains into the pNL-LucR.T2A backbone. Further, it suggests feasibility for analyzing the envecto domain derived from other virus clades in the pNL-LucR.T2A backbone.
57. Louder MK, Sambor A, Chertova E, et al. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 2005; 339:226-238. This important article from outside the review period shows both how the cell type from which HIV-1 is produced (PBMC versus 293T) and, expression of env in cis versus trans (pseudovirus) may affect sensitivity of the virus/pseudovirions to NAb. Importantly, data are provided that indicate the increased resistance of PBMC-derived virus may be more quantitative than qualitative, which supports the utility of using pseudovirions in assays to assess NAbs elicited by vaccine immunogens. (Pubitemid 41169790)
58. Blanco J, Bosch B, Fernandez-Figueras MT, et al. High level of coreceptorin-dependent HIV transfer induced by contacts between primary CD4 T cells. J Biol Chem 2004; 279:51305-51314. (Pubitemid 40017876)
59. Sato H, Orenstein J, Dimitrov D, et al. Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 1992; 186:712-724.
60. Sourisseau M, Sol-Foulon N, Porrot F, et al. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 2007; 81:1000-1012. (Pubitemid 46067924)
61. Dimitrov DS, Willey RL, Sato H, et al. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 1993; 67:2182-2190. (Pubitemid 23088394)
62. Jolly C, Sattentau QJ. Retroviral spread by induction of virological synapses. Traffic 2004; 5:643-650. (Pubitemid 39199128)
63. Jolly C, Mitar I, Sattentau QJ. Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells. J Virol 2007; 81:13916-13921. (Pubitemid 350247884)
64. Chen P, Hubner W, Spinelli MA, et al. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol 2007; 81:12582-12595. (Pubitemid 350085872)
65. Ganesh L, Leung K, Lore K, et al. Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J Virol 2004; 78:11980-11987. (Pubitemid 39390783)
66. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552-7557. This report describes the derivation and identification of transmitted/founder env sequences from acutely HIV-1 infected patients, and, thus, represents a wealth of available virologic reagents highly relevant to neutralization assays and vaccine development.
67. Salazar-Gonzalez J, Salazar M, Keele B, et al. Genetic identity, biological phenotype and evolutionary pathways of transmitted/founder viruses and their progeny in acute and early HIV-1 infection. J Exp Med 2009; 206:1273-1289. This report identifies complete genome sequences of transmitted/founder HIV-1 viruses. These sequences and the subsequent derivation of IMCs [68] represent useful virologic reagents for understanding HIV-1 transmission and immune monitoring assays.
68. Ochsenbauer-Jambor C, Ding D, Keele B, et al. Generation and biological characterization of infectious molecular clones derived from clade B HIV-1 transmitted/founder viruses [abstract number 492]. Conference on Retroviruses and Opportunistic Infections; 2009.
69. Moore JP, Burton DR. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat Med 2004; 10:769-771. (Pubitemid 39070840)